Pathway | P-value | FDR | # DEG |
---|---|---|---|
DEG highly-expressed in parenchyma vs. fat pad | Â | Â | Â |
   Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 0.0025 | 0.114 | 7 |
   Nitric Oxide Signaling in the Cardiovascular System | 0.0028 | 0.114 | 9 |
   Actin Cytoskeleton Signaling | 0.0001 | 0.014 | 22 |
   p53 Signaling | 0.0014 | 0.114 | 11 |
   Wnt/β-catenin Signaling | 0.0071 | 0.193 | 15 |
   PI3K/AKT Signaling | 0.0071 | 0.193 | 13 |
DEG highly-expressed in fat pad vs. parenchyma1 | Â | Â | Â |
   Propanoate Metabolism | 0.0000 | 0.000 | 12 |
   Metabolism of Xenobiotics by Cytochrome P450 | 0.0000 | 0.001 | 11 |
   Valine, Leucine and Isoleucine Degradation | 0.0000 | 0.001 | 11 |
   Butanoate Metabolism | 0.0001 | 0.002 | 10 |
   Glutathione Metabolism | 0.0001 | 0.002 | 9 |
   Pyruvate Metabolism | 0.0001 | 0.002 | 11 |
   Fatty Acid Metabolism | 0.0003 | 0.004 | 12 |
   Citrate Cycle | 0.0003 | 0.004 | 7 |
   Glycolysis/Gluconeogenesis | 0.0009 | 0.009 | 11 |
   Synthesis and Degradation of Ketone Bodies | 0.0020 | 0.016 | 4 |
   Fatty Acid Elongation in Mitochondria | 0.0030 | 0.022 | 4 |
   Oxidative Phosphorylation | 0.0085 | 0.055 | 13 |
   Tryptophan Metabolism | 0.0087 | 0.055 | 9 |
   Pentose Phosphate Pathway | 0.0098 | 0.056 | 5 |
   Mitochondrial Dysfunction | 0.0000 | 0.000 | 19 |
   LPS/IL-1 Mediated Inhibition of RXR Function | 0.0000 | 0.000 | 20 |
   Xenobiotic Metabolism Signaling | 0.0000 | 0.001 | 23 |
   Aryl Hydrocarbon Receptor Signaling | 0.0001 | 0.001 | 17 |
   Acute Phase Response Signaling | 0.0003 | 0.004 | 19 |
   LXR/RXR Activation | 0.0004 | 0.005 | 10 |
   Complement System | 0.0004 | 0.005 | 7 |
   TR/RXR Activation | 0.0013 | 0.012 | 11 |
   α-Adrenergic Signaling | 0.0013 | 0.012 | 12 |
   NRF2-mediated Oxidative Stress Response | 0.0014 | 0.012 | 18 |
   Cardiac β-Adrenergic Signaling | 0.0014 | 0.012 | 13 |
   cAMP-mediated Signaling | 0.0055 | 0.038 | 13 |
   IL-8 Signaling | 0.0081 | 0.055 | 16 |
   IGF-1 Signaling | 0.0098 | 0.118 | 11 |